Ironwood Pharmaceuticals (IRWD) Amortization of Deferred Charges (2013 - 2026)

Ironwood Pharmaceuticals has disclosed Amortization of Deferred Charges across 14 years of filings, most recently posting $419000.0 for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $419000.0, up 0.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (down 3.47% YoY), and the FY2025 annual result was $1.7 million, down 12.39% from the prior year.
• Amortization of Deferred Charges came in at $419000.0 for Q1 2026 at Ironwood Pharmaceuticals, roughly flat from $418000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $589000.0 in Q1 2024 to a low of $350000.0 in Q3 2024.
• The 5-year median for Amortization of Deferred Charges is $418000.0 (2025), against an average of $464941.2.
• Across the five-year window, Amortization of Deferred Charges plunged 93.49% in 2022 and jumped 46.75% in 2023, its largest moves.
• Ironwood Pharmaceuticals' Amortization of Deferred Charges stood at $400000.0 in 2022, then surged by 46.75% to $587000.0 in 2023, then declined by 29.3% to $415000.0 in 2024, then increased by 0.72% to $418000.0 in 2025, then advanced by 0.24% to $419000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $419000.0 (Q1 2026), $418000.0 (Q4 2025), and $418000.0 (Q3 2025), per Business Quant data.